I. Call to Order.................................................................Marty McKay

II. Parliamentary Business ......................................................Marty McKay
   A. Introduction of Members/Roll Call
   B. Approval of October 28, 2015 Meeting Minutes
   C. P & T Bylaws – Proposed Amendment

III. Ethics Reminders............................................................Kim Sullivan

IV. Reports.................................................................Melwyn Wendt
   A. Prior Authorization Monthly Report
   B. PDL Reflecting October 28, 2015 P&T Committee Recommendations

V. New Business............................................................Nina Bandali
   A. Therapeutic Class Reviews of Spring Drug Classes/Drug Manufacturer Testimony
      1. Analgesics, Narcotics Long
      2. Analgesics, Narcotics Short
      3. Angiotensin Modulator Combinations
      4. Angiotensin Modulators
      5. Antibiotics, GI
      6. Antibiotics, Inhaled
      7. Antibiotics, Topical
      8. Antibiotics, Vaginal
      9. Anticoagulants
     10. Antiemetic/Antivertigo Agents
     11. Antifungals, Oral
     12. Antifungals, Topical
     13. Antimigraine Agents, Triptans
     14. Antiparasitics, Topical
     15. Antivirals, Oral - New
     16. Antivirals, Topical
     17. Beta-Blockers
     18. Bladder Relaxant Preparations
     20. BPH Treatments
     21. Calcium Channel Blockers
     22. Cephalosporins and Related Antibiotics
     23. Fluoroquinolones, Oral
     24. GI Motility, Chronic - New
     25. Growth Hormone
     26. H. Pylori Treatment - New
27. Hepatitis C Agents  
28. Hypoglycemics, Incretin Mimetics/Enhancers  
29. Hypoglycemics, Insulin and Related Agents  
30. Hypoglycemics, Meglitinides  
31. Hypoglycemics, SGLT2  
32. Hypoglycemics, Sulfonylureas - New  
33. Hypoglycemics, TZD  
34. Immunosuppressives, Oral - New  
35. Lincosamides/Oxazolidinones/Streptogramins  
36. Lipotropics, Other  
37. Lipotropics, Statins  
38. Macrolides/Ketolides  
39. Multiple Sclerosis Agents  
40. Nitrofuran Derivatives - New  
41. Opiate Dependence Treatments  
42. PAH Agents, Oral and Inhaled  
43. Pancreatic Enzymes  
44. Phosphate Binders  
45. Pituitary Suppressive Agents, LHRH  
46. Platelet Aggregation Inhibitors  
47. Proton Pump Inhibitors  
48. Skeletal Muscle Relaxants  
49. Tetracyclines  
50. Ulcerative Colitis Agents  
51. Vasodilators, Coronary - New

VI. New Single Drug Reviews from Fall Classes.........................Nina Bandali  
1. Antihyperuricemics – Mitigare  
2. Antipsychotics - Aristada  
3. Antipsychotics – Vraylar  
4. COPD Agents – Spiriva Respimat  
5. COPD Agents – Utibron Neohaler  
6. COPD Agents – Seebri Neohaler  
7. Cytokine and CAM Antagonists – Xeljanz XR  
8. Intranasal Rhinitis Agents - Ticanase  
9. Progestational Agents - Makena  
10. Steroids, Topical High – Dermacinrx Silazone  
11. Steroids, Topical High – Silazone – II  
12. Stimulants and Related Agents – Quillichew ER  
13. Stimulants and Related Agents – Dyanavel XR

VII. Other Business

VIII. Next Steps  
A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

IX. Next Meeting Date – October 26, 2016 or November 2, 2016

X. Public Testimony